{"id":"atezolizumab-and-recombinant-human-hyaluronidase","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atezolizumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 and restoring anti-tumor T-cell immunity. The addition of recombinant human hyaluronidase (rHuPH20) degrades hyaluronic acid in subcutaneous tissue, enabling faster absorption and improved pharmacokinetics of the antibody when administered subcutaneously rather than intravenously.","oneSentence":"Atezolizumab is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with recombinant human hyaluronidase to enhance subcutaneous delivery and bioavailability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:56.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Urothelial carcinoma"},{"name":"Triple-negative breast cancer"},{"name":"Other solid tumors in phase 3 development"}]},"trialDetails":[{"nctId":"NCT07388524","phase":"PHASE3","title":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-09","conditions":"Lung Non-Small Cell Carcinoma","enrollment":336},{"nctId":"NCT05340309","phase":"PHASE2","title":"Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-12-07","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8","enrollment":5},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT03735121","phase":"PHASE3","title":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-27","conditions":"Non-Small Cell Lung Cancer","enrollment":438},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT04045028","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2019-07-22","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma","enrollment":41},{"nctId":"NCT03267940","phase":"PHASE1","title":"Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma","status":"TERMINATED","sponsor":"Halozyme Therapeutics","startDate":"2017-10-02","conditions":"Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atezolizumab + rHuPH20","Atezolizumab and Hyaluronidase","Atezolizumab and Hyaluronidase-tqjs","Atezolizumab and Recombinant Human Hyaluronidase-tqjs","Atezolizumab with rHuPH20"],"phase":"phase_3","status":"active","brandName":"Atezolizumab and Recombinant Human Hyaluronidase","genericName":"Atezolizumab and Recombinant Human Hyaluronidase","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Biologic","firstApprovalDate":"","aiSummary":"Atezolizumab is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with recombinant human hyaluronidase to enhance subcutaneous delivery and bioavailability. Used for Non-small cell lung cancer (NSCLC), Urothelial carcinoma, Triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}